List view / Grid view

Michael Flanagan (Avidity Biosciences)

 

article

Advancing AOCs to transform the delivery of RNA therapeutics

In this article, Dr Michael Flanagan discusses how a new…

11 December 2023 | By ,

In this article, Dr Michael Flanagan discusses how a new class of medicines called antibody oligonucleotide conjugates (AOCs) have the potential to overcome a major challenge encountered with many established RNA-based therapeutics: delivery to tissues outside the liver. Last year, AOCs demonstrated the first-ever successful targeted delivery of RNA into…